Sunshine Biopharma Inc.: Sunshine Biopharma Completes Application to Uplist to OTCQB
MONTREAL, QC / ACCESSWIRE / January 27, 2021 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has successfully completed and submitted the application to uplist to the OTCQB. While the Company is currently a fully reporting issuer trading on OTC Markets PINK, management has determined that an uplist to OTCQB is aligned with the Company s overall growth trajectory as it will allow institutional investors to participate.
The OTCQB Venture Market, operated by OTC Markets Group Inc. in New York City, is a premier market for early stage and developing companies. As a verified market with efficient access to U.S. investors, OTCQB helps companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation.
Sunshine Biopharma Completes Application to Uplist to OTCQB
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
Vitamin D-Mangel im Corona-Winter? Wann ergänzende Präparate helfen – und wann nicht
ruhrnachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ruhrnachrichten.de Daily Mail and Mail on Sunday newspapers.
(2)
MONTREAL, QC / ACCESSWIRE / January 14, 2021 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $1,050,000 that the Company has received to date under this financing. The proceeds will be used for the ongoing development of the Company s Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company s flagship anticancer compound targeted for pancreatic cancer.
Sunshine Biopharma Inc. CFO, Camille Sebaaly stated, As a company, we continue to forge forward in our development of a COVID treatment and our anticancer compounds. This investment capital has been integral to our progress in each of these sectors.